Yüklüyor......
Trametinib: A Targeted Therapy in Metastatic Melanoma
Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib for the treatment of BRAF V600E or V600K mutated melanoma. It is a once-daily oral medication that was approved based on progression-free survival and overall survival advantage compared to chemotherapy....
Kaydedildi:
| Yayımlandı: | J Adv Pract Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Harborside Press
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570520/ https://ncbi.nlm.nih.gov/pubmed/31249721 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|